FIELD: medicine.
SUBSTANCE: composition for treating autoimmune diseases consists of trigoneoside Ib and vicenin-1, together with an excipient where it is necessary, wherein the trigoneoside Ib concentration falls within the range of 40 to 90 wt %, whereas the vicenin-1 concentration ranges from 1 to 20 wt %. The invention also refers to a method for producing the above composition and a method of treating autoimmune diseases involving administering the above composition.
EFFECT: invention is characterised by high effectiveness on various autoimmune diseases.
17 cl, 6 dwg, 8 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMINOPYRIMIDINYL DERIVATIVES | 2021 |
|
RU2817349C1 |
| TERT-BUTYL-N-[2-{4-[6-AMINO-5-(2,4-DIFLUOROBENZOYL)-2-OXOPYRIDIN-1(2H)-YL]-3,5-DIFLUOROPHENYL}ETHYL]-L-ALANINATE OR SALT, HYDRATE OR SOLVATE THEREOF | 2013 |
|
RU2676329C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC INFLAMMATION AND INFLAMMATORY DISEASES | 2012 |
|
RU2635188C2 |
| N-SUBSTITUTED DIOXOCYCLOBUTENYLAMINO-3-HYDROXYPICOLINAMIDES SUITABLE AS CCR6 INHIBITORS | 2019 |
|
RU2784831C2 |
| PROTEINKINASE C INHIBITORS USED FOR TREATING AUTOIMMUNE DISEASES AND GRAFT REJECTION | 2005 |
|
RU2413511C2 |
| NEW CDK8/19 INHIBITORS | 2019 |
|
RU2754441C2 |
| AMINOPYRAZOLES AS SELECTIVE JANUS KINASE INHIBITORS | 2017 |
|
RU2757218C2 |
| CONCENTRATED METHOTREXATE SOLUTIONS | 2007 |
|
RU2403044C1 |
| CYSTATHIONINE-G-LYASE (CSE) INHIBITORS | 2013 |
|
RU2640418C2 |
| CRYSTALLINE HUMAN IL-12 ANTIBODIES | 2008 |
|
RU2476442C2 |
